If you have been reading about cold chain and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or inert plastic | Compatibility depends on peptide and solvent |
| Headspace gas | Nitrogen or argon | Used to limit oxygen exposure |
| Common reconstitution solvent | Water or buffered aqueous solution | Organic co-solvents may be needed for hydrophobic peptides |
| Freeze-thaw stability | Varies by peptide | Aliquoting reduces repeated cycles |
| Documentation | Lot, date, concentration, storage location | Supports traceability and reproducibility |
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
They were the first set of nonsense mutations to be discovered, isolated by Richard H. Epstein and Charles Steinberg and named after their friend and graduate Caltech student Harris Bernstein, whose last name means "amber" in German (cf. Bernstein). Viruses with amber mutations are characterized by their ability to infect only certain strains of bacteria, known as amber suppressors. These bacteria carry their own mutation that allows a recovery of function in the mutant viruses. For example, a mutation in the tRNA that recognizes the amber stop codon allows translation to "read through" the codon and produce a full-length protein, thereby recovering the normal form of the protein and "suppressing" the amber mutation. Thus, amber mutants are an entire class of virus mutants that can grow in bacteria that contain amber suppressor mutations. Similar suppressors are known for ochre and opal stop codons as well. tRNA molecules carrying unnatural aminoacids have been designed to recognize the amber stop codon in bacterial RNA. This technology allows for incorporation of orthogonal aminoacids (such as p-azidophenylalanine) at specific locations of the target protein.
It was armed with four .30 caliber (7.62 mm) AN/M2 Browning machine guns in the wings and two .50 caliber (12.7 mm) AN/M2 Browning machine guns mounted under the engine and firing through the propeller arc using a gun-synchronizing gear. While the USAAC could block any sales it considered detrimental to the interests of the US, the NA-73 was considered to be a special case because it had been designed at the behest of the British and all dealings were directly between the BPC and NAA, and did not involve the US Army or Wright Field in any way. In September 1940, a further 300 NA-73s were ordered by the MAP. To ensure uninterrupted delivery, Colonel Oliver P. Echols arranged with the Anglo-French Purchasing Commission to deliver the aircraft and NAA gave two examples (41-038 and 41-039) to the USAAC for evaluation. The Mustang I (NA-73 and NA-83) and the Ia (NA-91), produced for the British, were not equivalent to the P-51A which was a later model (NA-99). Two British Mustang Is were held back by the USAAF and given the provisional model number XP-51. The USAAF held back 57 Mustang Ia aircraft armed with 4 x 20mm Hispano cannon, from the third British order, converting most of them to tactical reconnaissance aircraft and designating them P-51-2/F6A. North American retained the second aircraft of this batch to help develop the P-51A. The Allison engine in the Mustang I had a single-stage supercharger that caused power to drop off rapidly above 15,000 feet (4,600 m). This made it unsuitable for use at the altitudes where combat was taking place in Europe.
== History == The idea that the stomach produces a hormone to trigger acid secretion was first put forward by British physiologist John Sydney Edkins in 1905. Working with cats, he found that injecting extracts from the stomach lining causes an increase in acid production, and he called the substance responsible "gastrin". His theory was met with skepticism after histamine was discovered in 1910, as it had a similar effect on the stomach, leading many scientists to doubt whether gastrin was a separate hormone at all. The debate was largely settled in 1942, when Simon Komarov published research showing that a gastrin extract could stimulate acid secretion on its own, separate from histamine. Building on this work, Roderic Gregory and Hilda Tracy isolated the hormone in purified form in the early 1960s and identified two closely related versions, which they named gastrin I and gastrin II. Chemist George Kenner then determined the full amino acid sequence of both peptides, making gastrin the first gut hormone to have its complete structure worked out.
The binding of tyrosine hydroxylase to membranes involves the N-terminal region of the enzyme, and may be regulated by a three-way interaction between 14-3-3 proteins, the N-terminal region of tyrosine hydroxylase, and negatively charged membranes. Tyrosine hydroxylase can also be regulated by inhibition. Phosphorylation at Ser40 relieves feedback inhibition by the catecholamines dopamine, epinephrine, and norepinephrine. The catecholamines trap the active-site iron in the Fe(III) state, inhibiting the enzyme. It has been shown that the expression of tyrosine hydroxylase can be affected by the expression of SRY. The down regulation of the SRY gene in the substantia nigra can result in a decrease in tyrosine hydroxylase expression. Long term regulation of tyrosine hydroxylase can also be mediated by phosphorylation mechanisms. Hormones (e.g. glucocorticoids), drugs (e.g. cocaine), or second messengers such as cAMP increase tyrosine hydroxylase transcription. Increase in tyrosine hydroxylase activity due to phosphorylation can be sustained by nicotine for up to 48 hours. Tyrosine hydroxylase activity is regulated chronically (days) by protein synthesis.
Sources: en.wikipedia.org
Excessive amounts of valproic acid can result in somnolence, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography. In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9). In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body. Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored. Supplemental L-carnitine is indicated in patients having an acute overdose and also prophylactically in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly than L-carnitine.
== Society and culture == A team of researchers led by Changhan Lee, a member of the Pinchas Cohen laboratory at the USC Davis School of Gerontology, discovered MOTS-c in 2015. Subsequent research by Lee and colleagues linked administration of MOTS-c to improved physical fitness, decreased obesity, and longer healthy lifespans in mice. MOTS-c is not approved to treat any medical condition and is banned by the World Anti-Doping Agency, explicitly beginning in 2024. Despite a lack of robust human data, usage as an injectable supplement as part of the "peptide stacking" trend has been reported.
== Diagonals == If e, f, g and h are the tangent lengths from A, B, C and D respectively to the points where the incircle is tangent to the sides of a tangential quadrilateral ABCD, then the lengths of the diagonals p = AC and q = BD are
Sources: en.wikipedia.org
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.
Aliquoting divides a solution into smaller portions so that each portion is handled once. This reduces repeated freeze-thaw cycles and limits contamination risk. It also makes it easier to track usage and maintain consistent test conditions.
Refreezing is possible for some peptides but can promote aggregation or precipitation. The effect depends on the peptide, solvent, concentration, and freezing rate. Many laboratory protocols therefore recommend single-use aliquots instead of repeated refreezing.
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.